clinical trial · NCT05125562
Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19
Direct Biologics, LLC·phase2·withdrawn
COVID-19ExoFlo
brief summary
Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19) To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles, ExoFlo, as treatment for mild-moderate COVID-19.
started
Dec 7, 2022
primary completion
Mar 7, 2023
completion
Mar 7, 2023
last updated
Feb 13, 2024
official title
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol